You just read:

Achelios Therapeutics Concludes Successful Type C Meeting with FDA Regarding Its Lead Product, TOPOFEN™, for Prevention and Treatment of Migraine

News provided by

Achelios Therapeutics

Jun 14, 2017, 08:31 ET